RESULTS OF AN OPEN, MONOCENTERED NON-RANDOMISED, WITHOUT CONTROL GROUP, OBSERVATIONAL QUALITY OF LIFE EVALUATION STUDY IN PATIENTS WITH IDIOPATHIC JUVENILE ARTHRITIS TREATED WITH ETARNECEPT IN COMBINATION WITH METHOTREXATE

Study objective — to evaluate etarnecept influence on quality of life of idiopathic juvenile arthritis patients’ quality of life. 25 patients with poly- and oligoarthritides aged 8 (6; 11) years. Before etarnecept use quality of life of all patients was significantly lower that that of healthy children judging upon children’s own opinion and that of their parents. No longer that after 1 month since the beginning of etarnecept treatment 92% of patients claimed significant increase in their quality of life (according to patients’ opinion, total score increase from 53 to 59, from 49 to 60, according to parents (p &lt; 0,001). After 12 months of treatment 68 % of patients had quality of life similar to the one of healthy children.Key words: juvenile idiopathic arthritis, etarnecept, methotrexate, quality of life, efficacy, safety. (Voprosy sovremennoi pediatrii — Current Pediatrics. — 2011; 10 (6): 26–34.)</p

RESULTS OF AN OPEN, MONOCENTERED NON-RANDOMISED, WITHOUT CONTROL GROUP, OBSERVATIONAL QUALITY OF LIFE EVALUATION STUDY IN PATIENTS WITH IDIOPATHIC JUVENILE ARTHRITIS TREATED WITH ETARNECEPT IN COMBINATION WITH METHOTREXATE

Study objective — to evaluate etarnecept influence on quality of life of idiopathic juvenile arthritis patients’ quality of life. 25 patients with poly- and oligoarthritides aged 8 (6; 11) years. Before etarnecept use quality of life of all patients was significantly lower that that of healthy children judging upon children’s own opinion and that of their parents. No longer that after 1 month since the beginning of etarnecept treatment 92% of patients claimed significant increase in their quality of life (according to patients’ opinion, total score increase from 53 to 59, from 49 to 60, according to parents (p &lt; 0,001). After 12 months of treatment 68 % of patients had quality of life similar to the one of healthy children.Key words: juvenile idiopathic arthritis, etarnecept, methotrexate, quality of life, efficacy, safety. (Voprosy sovremennoi pediatrii — Current Pediatrics. — 2011; 10 (6): 26–34.

THERAPEUTIC CAPABILITIES OF ETHANERCEPT IN TREATMENT OF SYSTEMIC JUVENILE RHEUMATOID ARTHRITIS

The article presents a clinical case of severe systemic juvenile rheumatoid arthritis, refractory to traditional immunosuppressive treatment and with insufficient efficacy of chimeric homogenous anti-TNF-a antibodies. The patient received 2 courses of anti-Blymphocyte’s- CD20-antibodies that helped to arrest all systemic manifestations of the disease. Articular syndrome was arrested only with the help of soluble receptors to TNF a — ethanercept, given in following dose — 0.4 mg per kg of body mass. The patient has been on treatment with ethanercept for 24 weeks. Joint tenderness and exudation were diminished already after the first 4 weeks of treatment, also there was a dramatic increase in joint motion range. After 6 months of therapy we have managed to improve the patients and his family quality of life.Key words: children, juvenile rheumatoid arthritis, ethanercept, treatment.(Voprosy sovremennoi pediatrii — Current Pediatrics. 2011; 10 (3): 141–149

EFFICACY OF ETANERCEPT IN CHILD WITH SEVERE POLYARTICULAR TYPE OF JUVENILE RHEUMATOID ARTHRITIS

The article presents a case report of severe and prolonged polyarticular rheumatoid arthritis resistant to the treatment with classic immunosuppressive agents, nonsteroidal anti-inflammatory drugs and corticosteroids. Authors describe successful treatment with soluble receptors to TNF _ — etanercept 0.4 mg for 1 kg of body weight during 36 weeks. Pain and exudative inflammation in joints lessened and the range of motions in joints increased in 4 weeks after the beginning of treatment. 9 months of treatment significantly increased the quality of life of a child and parents.Key words: children, juvenile rheumatoid arthritis, etanercept.(Voprosy sovremennoi pediatrii — Current Pediatrics. 2011; 10 (2): 184–192)</span

EFFICACY OF ETANERCEPT IN CHILD WITH SEVERE POLYARTICULAR TYPE OF JUVENILE RHEUMATOID ARTHRITIS

The article presents a case report of severe and prolonged polyarticular rheumatoid arthritis resistant to the treatment with classic immunosuppressive agents, nonsteroidal anti-inflammatory drugs and corticosteroids. Authors describe successful treatment with soluble receptors to TNF _ — etanercept 0.4 mg for 1 kg of body weight during 36 weeks. Pain and exudative inflammation in joints lessened and the range of motions in joints increased in 4 weeks after the beginning of treatment. 9 months of treatment significantly increased the quality of life of a child and parents.Key words: children, juvenile rheumatoid arthritis, etanercept.(Voprosy sovremennoi pediatrii — Current Pediatrics. 2011; 10 (2): 184–192